Newly listed ePAT Technologies , a graduate team from ON Accelerate2, is set to achieve a number of important milestones in the development of its mobile medical app that uses facial recognition software to assess and manage pain.
The company (ASX: EPT) recently completed a pilot implementation study at Brightwater’s Aged Care Home in Inglewood, Western Australia. The study was designed to assess the feasibility of using ePAT to assess and monitor pain in the aged care setting. The study involved 36 residents and 18 staff, with 580 pain assessments completed during an 8-week period. The results of the trial are now being analysed and are due for release in February 2017.
According to ePAT CEO Philip Daffas, this and other validation studies will underpin important regulatory approvals in the future. “The validation and implementation results are key requirements for regulatory approval. We are in the process of completing the technical files and other documentation required to apply for approval in Europe and Australia,” said Daffas.
ePAT were successful in gaining an entry into ON Accelerate2 in 2016, with their mobile application (ePAT App) that uses cameras in smartphones and tablets to capture a brief video of the person. The video is then analysed in real time using facial recognition software to detect the presence of facial micro- expressions that are indicative of the presence of pain
This data is then combined with other indicators of pain, such as vocalisations, behaviours and movements captured through the ePAT App to calculate a pain severity score.
The app works in the device without the need for wi-fi to deliver pain assessments that are simple, accurate, objective and reproducible.
The other key market application for the App is the paediatric setting. The development of the Children’s App is in progress with the company’s international technology partners nViso. A number of different facial assessment models for the children’s app have been evaluated and a preferred model has been selected for development.
Since completing ON Accelerate in July 2016, the ePAT team has been re-invigorated via a number of senior team additions. Daffas has taken over as CEO while experienced venture capital manager John Murray has joined as Non-Executive Chairman of the Board.
CEO Philip Daffas said he was pleased that the company was on track with key milestones. “We have strong supportive data and positive customer feedback from our clinical work. We are on target for the initial dementia product launch in the second half of 2017. The team is focused and working diligently to achieve our end goal of a commercializing this technology to improve health outcomes.”